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Abstract
Obesity and its comorbidities exhibit a gender-related dimorphism. Obese males 
tend to accrue more visceral fat leading to abdominal adiposity, which shows a strong 
correlation with serious obesity-associated comorbidities, cardiovascular diseases 
and cancers. In contrast, obese females accumulate excessive fatty tissue predomi-
nantly subcutaneously enjoying strong protection from the obesity-related diseases. 
The health advantage of obese women as compared with obese men may be attrib-
uted to their higher estrogen production and an increased transactivation of estrogen 
receptors (ERs). The recently clarified intracrine, paracrine, and endocrine functions 
of adipose tissue illuminate that concentrations of estrogens and the suitable expres-
sion and activity of ERs strongly define all regulatory functions in both men and 
women. All well-known cancer risk factors are in correlation with defects of estrogen 
signaling in partnership with glucose intolerance as estrogen regulates all steps of 
glucose uptake. In central obesity, increased secretions of cytokines and growth 
factors are not causal factors of developing insulin resistance, and unrestrained cell 
proliferation, but rather, they are compensatory processes so as to increase estrogen 
synthesis and ER transactivation. In conclusion, a causal therapy against obesity and 
obesity-related diseases aims to improve estrogen signaling in both men and women.
Keywords: obesity, insulin resistance, estrogen signaling, cancer risk, cardiovascular 
disease, estrogen receptor, IGF-1, low-grade inflammation, inflammatory cytokines
1. Introduction
Gender-related differences in the risk for obesity-associated serious diseases, such 
as type 2 diabetes, cardiovascular lesions, and cancers, are well established [1, 2].
Fat deposition exhibits a strong sexual dimorphism defined by genetic factors 
[3]. Among healthy lean people, women have a higher body fat content than men. In 
obesity, males tend to accrue excessive visceral fat leading to abdominal adiposity, 
which shows a strong correlation with serious obesity-associated comorbidities. In 
contrast, obese females accumulate excessive fat deposition predominantly subcu-
taneously in the gluteofemoral region, gaining protection from the obesity-related 
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diseases. However, after menopause, excessive fat depositions in obese women show 
a shift to favor the visceral depot in a male-like manner, resulting in an increased 
risk for obesity and associated comorbidities [4]. Considering the gender and age-
related differences in the epidemiology of obesity and obesity-associated diseases, 
an imbalance of sexual hormone signaling emerges as a crucial player in the dys-
regulation of adipose tissue in obese patients [5].
Both clinical and experimental results suggest that obesity, particularly a 
visceral accumulation of fatty tissue, leads to insulin resistance, which is a defect of 
insulin-assisted cellular glucose uptake [6]. Dysregulation of glucose uptake may 
induce serious disorders in the gene regulation of cellular metabolism, growth, dif-
ferentiation, and mitotic activity as glucose is the most important fuel of genomic 
machinery in mammalian cells [7].
Insulin resistance was the first one among revealed cancer risk factors detrimen-
tally affecting cellular signaling functions [8]. Later on, defective estrogen signaling 
emerged as a second cancer risk factor, which directly deteriorates the functions of 
genomic machinery [9]. In the meantime, a central role of sexual steroid synthesis 
and estrogen signaling emerged as the chief regulator of all extragonadal tissues 
including adipose tissue [10]. Finally, a fundamental role of estrogen signaling in 
the regulation of both somatic and reproductive functions of mammalian cells was 
exposed [11].
The recently clarified intracrine, paracrine, and endocrine functions of adipose 
tissue illuminate that concentrations of estrogens, and the appropriate expression 
and activity of their receptors, strongly define the regulatory functions of central 
adipose tissue in both men and women [12]. Decreased estrogen signaling induces 
central obesity through an increased lipogenesis and insulin resistance of abdomi-
nal adipocytes. The excessive lipid storage strongly inhibits the signaling crosstalk 
between adipose cells and visceral organs, including intestine, liver, pancreas, 
kidneys and cardiovascular system. The disturbed inter-tissue crosstalk may cause 
defects in both metabolic and mitotic activities of parenchymal and stromal cells of 
different organs and induces serious, life-threatening diseases.
Understanding the pivotal regulatory roles of healthy abdominal fatty tissue 
in signal transduction may appropriately answer the question: how can abundant 
visceral fat deposition lead to serious, life-threatening diseases, such as cardiovas-
cular lesions and malignancies in different organs?
2.  Weak estrogen signaling in men and postmenopausal women 
provokes an increased prevalence of abdominal obesity and  
glucose intolerance
In obese patients, an excessive fat deposition in the intra-abdominal adipose 
depot is strongly associated with an increased risk for type 2 diabetes, cardio-
vascular diseases, and cancers developing at different sites [13]. Gender-related 
dimorphism of adipocyte behavior and fatty tissue accumulation suggests that 
health advantages of obese women as compared with obese men may be attributed 
to stronger estrogen signaling and an increased activation of estrogen-regulated 
genes [14].
In obese men, an excessive abdominal fatty tissue deposition is characteristic. 
Male-like abdominal obesity is strongly associated with different stages of insulin 
resistance and an increased risk for obesity-associated comorbidities including 
cancer [3].
Among obese premenopausal women with regular ovulatory cycles, a female-
type gluteofemoral deposition of adipose tissue may be associated with the 
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maintenance of healthy insulin sensitivity, whereas they have no increased risk for 
either cardiovascular or neoplastic diseases [15]. Abdominal adipocytes of healthy 
women exhibit higher insulin sensitivity as compared with those of men [16]. In 
contrast, in premenopausal obese women with anovulatory infertility or disorders 
of menstrual cycles, a male-like abdominal obesity and deepening insulin resistance 
may develop in correlation with the defect of estrogen signaling [17].
In women, menopause is a physiological model revealing how decreased estrogen 
level may induce adiposity and its comorbidities. In obese, postmenopausal women, 
an increased inclination to a male-like central obesity and associated insulin resis-
tance may be experienced [4, 5]. Increased prevalence of abdominal obesity and 
obesity-related diseases in postmenopausal women strongly suggests that decreased 
estrogen signaling may have pivotal roles in the dysregulation of lipid metabolism, 
glucose tolerance, and cell proliferation [18, 19]. In contrast, hormone replacement 
therapy after menopause reduces the accumulation of visceral adipose tissue and 
improves insulin sensitivity via an activation of estrogen-regulated genes [20].
Inherited serious mutations on estrogen receptor alpha gene (ESR1) or aroma-
tase coding CYP19 gene may result in extreme defects of estrogen signaling and 
lead to insulin-resistant states and premature cardiovascular diseases in both male 
and female cases [21–23].
In rodents, estrogen withdrawal via ovariectomy consistently increases adipos-
ity-associated body weight and glucose intolerance, while estrogen treatment results 
in weight loss and a restoration of insulin sensitivity [24, 25]. Aromatase knock-out 
(ArKO) transgenic mice with inactivated aromatase enzyme are unable to synthe-
size estrogen and exhibit increasing obesity and insulin resistance with associated 
compensatory hyperinsulinemia in males and females [26]. ER-alpha knock-out 
(ERαKO) male and female mice similarly exhibit metabolic syndrome-like pheno-
types, including obesity, glucose intolerance, hyper-insulinemia, and decreased 
energy expenditure [27].
In ovariectomized obese mice, inoculated T47D tumor cells exhibited an intense 
proliferation, while estrogen supplementation suppressed the survival of inoculated 
tumor cells [28]. Ovariectomized female mice were fed diets to induce obesity and 
were inoculated with mouse mammary cancer cells. Estrogen substitution triggered 
a loss of body fat, improved insulin sensitivity, and suppressed the proliferation of 
inoculated tumors [29].
In conclusion, either estrogen deficiency or estrogen receptor (ER) resistance 
may have a crucial role in the dysregulation of both lipid storage and glucose uptake 
in adipocytes resulting in obesity and type 2 diabetes as clinical manifestations. 
Estrogen substitution seems to be a good strategy against obesity and associated 
chronic diseases including cancer.
3.  Obesity-associated failure of estrogen signaling is a stronger cancer 
risk for males having low baseline estrogen levels
Systematic review and meta-analysis of literary data help to assess the associa-
tions between obesity and cancer risk in males and females [30]. Among men, obe-
sity disproportionately increases the prevalence of cancers developing at different 
sites. These observations strongly suggest that the health advantage in obese women 
may be attributed to their estrogen predominance supplying defense against failures 
in DNA replication [31].
In epidemiologic studies, a male predominance was experienced in esophageal 
adenocarcinoma incidence [32]. In a clinical study, oral cancer showed a conspicuous 
male predominance, while from 50 to 52 years of age, oral cancer incidence among 
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postmenopausal women showed a slow and, later, a steep increase in correlation with 
the loss of estrogen exposure [33]. Results of meta-analyses do indicate that the asso-
ciation between obesity and an increased risk for gastric cancer is stronger in men than 
in women and the correlation significantly increases with increasing BMI among men 
[34]. Colorectal cancer shows a high prevalence among men, while women are rela-
tively protected against this tumor [35]. Furthermore, hormone replacement therapy 
provides an additive protective effect against colon tumors in postmenopausal 
women. Obesity increases the risk for colorectal cancer in both men and women; 
while in males, associations between excessive adiposity and colon cancer risk seem 
to be much stronger [30]. Obesity and related metabolic disorders are high risk fac-
tors for primary liver cancer [36]. The associations are stronger in men, especially in 
patients with underlying liver disease, such as HCV infection or cirrhosis.
Unexpectedly, the risk for kidney cancer is higher in obese women than in men 
with increasing BMI [37]. Overweight and obese patients were found to have 
elevated risks of renal cell cancer in a dose-response manner, with an estimated 24% 
increase for men and a 34% increase for women by every 5 kg/m2 increase in body 
mass index (BMI) [30]. Conversely, data from the National Cancer Database during 
a 10-year period were analyzed and a ratio of 1.65 of renal cell carcinoma risk for 
males compared to females was established disregarding the impacts of differences in 
BMI. Nevertheless, the mean age of kidney cancer cases was greater in females (64.3) 
than in males (60.9) (p < 0.001) [38]. In obese women, a long-lasting postmenopausal 
decrease in estrogen synthesis may be an additional risk for kidney cancer, provoking 
an inverse gender-related disparity for kidney cancer in an aged population.
Breast cancer in women is the most frequently diagnosed malignant tumor, while 
in men, it is an extremely rare disease, accounting for less than 1% of all breast 
cancer cases [39]. Since high estrogen levels are mistakenly regarded as fuels for 
breast cancer growth, the strong protection of males against breast cancer may 
be deceivingly attributed to their physiologically lower estrogen levels. The causal 
factors of male breast cancer are quite similar to those of female breast malignan-
cies—obesity, type 2 diabetes and male infertility [39], which are strongly associ-
ated with insulin resistance and deficient estrogen signaling. Healthy female breasts 
exhibit high estrogen demand attributed to their physiologic cycling activity, and 
they are highly vulnerable even to slightly defective estrogen signaling. In contrast, 
in resting male breasts, very serious defects of estrogen signaling may be regarded 
as dangerous regulatory disorders leading to an increased risk for cancer [31].
Obesity equivocally increases the incidence of breast cancer among males, pre-
sumably through similar mechanisms as in case of females [40]. However, among 
women, an apparently ambiguous interaction can be observed between obesity and 
breast cancer risk depending on the menopausal status of patients [41]. In young 
women before menopause, obesity is erroneously regarded to exhibit a protective 
effect against breast cancer. Conversely, in postmenopausal older cases, there is a 
strong direct correlation between adiposity and mammary cancer risk. Obesity is 
associated with dysmetabolism and endangers the healthy equilibrium of sexual 
hormone production. In reality, among premenopausal women, obesity-associated 
insulin resistance is moderate, being counteracted by their maintained or increased 
circulating estrogen levels [15, 42]. In conclusion, it is not obesity but rather the still 
suitable estrogen level that may be protective against breast cancer in young women. 
Obese postmenopausal women, who had never used hormone replacement therapy 
(HRT), exhibit fairly high breast cancer risk in association with their continuously 
decreasing estrogen levels [43]. In contrast, obese postmenopausal women using 
hormone replacement therapy (HRT) show a significantly reduced breast cancer 
risk attributed to the protective effect of estrogen substitution [44, 45].
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The higher risk for obesity-associated cancer among men and postmenopausal 
women as compared with premenopausal cases suggests that the weaker the 
estrogen signaling in abdominal adipocytes, the stronger is the defect of DNA repair 
leading to an increased risk for cancer [15, 42].
4.  Central adipose tissue is a hub in the signaling network that controls 
and regulates visceral organs via an inter-tissue crosstalk
Adipose tissue stores excess calories in the form of lipid. In addition, adipose 
tissue is an endocrine organ regulating the functional activity of both adjacent and 
remote organs [46].
Adipose tissue is principally deposited in two locations. Centrally positioned fatty 
tissue within the trunk and abdomen closely surrounds the visceral organs, while 
the subcutaneously positioned adipose tissue covers the skeletal muscles [2]. The close 
vicinity between central fatty tissue and internal organs suggests that adipocyte sig-
naling in this region may regulate vital functions affecting the health of whole body, 
while subcutaneous adipocytes primarily confer their messages to skeletal muscles 
and skin. Differences in fatty tissue locations strongly suggest that in pathological 
situations included obesity, the dysregulation of central adipocytes is a much higher 
health risk as compared with that of their peripheral counterparts.
In healthy nonobese people, abdominal adipose tissue provides a strong mechan-
ical support for all internal organs [2]. Visceral fat is largely located in the omental 
and mesenteric adipose tissue in the vicinity of stomach, intestines, liver, and 
pancreas. Adipose tissue deposition is also characteristic within the visceral pericar-
dium surrounding the myocardium and coronary arteries. Kidneys and the attached 
adrenal glands are embedded into an abundant fatty tissue capsule. Central adipose 
tissue is a crucial fat store providing standby energy for physiologic functions and 
even for the functional activation of visceral organs among various circumstances.
On the other hand, central adipose tissue is a complex and highly active endo-
crine organ exerting essential regulatory functions through autocrine, paracrine, 
and endocrine mechanisms [47]. In addition to the mass of adipocytes, adipose 
tissue contains a connective tissue matrix comprising fibrocytes, nerves, vessels, 
and immune cells functioning as an integrated unit.
The receptor systems of adipocytes, fibrocytes, and immune cells collect numer-
ous afferent signals arriving from adjacent or remote organs and the central nervous 
system, while they respond through the secretion of signaling molecules, such as 
steroid hormones, adipokines, growth factors, and cytokines.
5.  Circulating and locally synthesized estrogen hormones regulate the 
functional activity of adipose tissue
Sex steroids, particularly estrogens, play a pivotal role in the regulation of 
all tissues in the body [10]. Estrogen-activated ERs are central regulators of the 
metabolic status, growth, differentiation, and proliferation of cells in mammalians. 
Estrogen-regulated genes control signaling functions of the whole body via a bal-
anced activation of ERs through liganded and unliganded pathways [48]. Estrogens 
are the regulators of crosstalks between adipose tissue and adjacent visceral organs 
via an appropriate expression of signaling molecules in both males and females.
Physiological cellular mechanisms require not only suitable estrogen concentra-
tions but also appropriate expression and activity of ERs in the targeted tissues. 
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The presence of both isomers, ER-alpha and ER-beta, was confirmed in adipocytes 
deriving from both subcutaneous and intra-abdominal adipose tissue, suggesting 
that adipose tissue function is strongly defined by suitable estrogen signaling [49]. 
Lower prevalence of visceral adiposity in women than in men arises from the high 
expression and activity of ERs in female abdominal adipocytes being capable of 
downregulating both adipogenesis and lipid storage [50].
The gonads, ovary, and testis are the primary sites of estrogen synthesis in mam-
mals. Extragonadal estrogen synthesis in adipose tissue was first published in 1974, 
based on the unexpected observation that androgens were converted to estrogens 
by aromatase enzyme in adipose tissue [51]. From that time onward, estrogen 
synthesis and the expression of estrogen receptors have been revealed in several 
organs [52]. All tissues expressing estrogen receptors are considered to be targets of 
estrogenic regulation.
Adipose tissue is considered to be a major source of estrogen synthesis among 
extragonadal sites in both women and men, and it increasingly contributes to the 
circulating estrogen concentration with aging [12]. In adipose tissue, C19 steroids 
are essential precursors of estrogen synthesis and the locally synthesized CYP19 
aromatase enzyme is able to convert C19 steroids to estrogens [53]. The prerequisite 
of estrogen synthesis is the local expression of aromatase enzyme, which strongly 
defines the local estrogen production. In extra-gonadal tissues, the expression 
level of aromatase enzyme shows strong parallelism with the intensity of estrogen 
synthesis. Extragonadal sites included adipose tissue are unable to synthesize C19 
steroids; hence, their estrogen synthesis is limited by the precursor supply from 
external sources [53].
Estrogens synthesized in adipose tissue are thought to act locally, in an autocrine 
manner, while they may have sufficient concentration in the adjacent organs too so 
as to induce ER activation in a paracrine manner. The systemic, endocrine effects of 
locally synthesized estrogens are limited [54]. Appropriate local estrogen concen-
tration may exert its biological activity via activation of ERs, which are members of 
the nuclear receptor superfamily.
Increased estrogen concentrations upregulate estrogen signaling through a DNA 
stabilizer circuit and lead to a higher expression of ERs, genome stabilizer proteins, 
and aromatase enzyme [11, 55]. In contrast, estrogen deficiency or a defect of ER 
activation causes dysregulation in adipocytes and leads to a derangement of their 
signaling functions.
The noteworthy volume of central adipose tissue and the remarkable estrogen 
synthesis of adipocytes may support the fact that estrogen signaling has a crucial 
role in controlling and orchestrating the signaling network of both adjacent organs 
and the whole body.
6.  Estrogen-regulated genes orchestrate the physiological functions of 
adipose tissue and visceral organs
Estrogen-activated ERs are the chief regulators of somatic and reproductive cel-
lular functions suggesting that a defect in estrogen signaling may produce dysregu-
lation and leads to serious diseases [48]. Current literary data support that activated 
ERs in adipocytes protect against fat deposition, insulin resistance, inflammation, 
and fibrosis of adipose tissue [Davis]. Moreover, body fat mass deposition is defined 
by the level of estrogen signaling in both men and women [56]. Healthy, insulin-
sensitive adipose tissue regulates the glucose homeostasis and balanced lipolysis/
lipogenesis of adjacent tissues, included liver, skeletal muscles, and further organs 
via a tissue crosstalk [57].
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6.1 Adipose tissue
Estradiol-induced activation of ER-alpha upregulates all steps of cellular glucose 
uptake increasing the insulin sensitivity of adipocytes [58]. In mature adipocytes, 
estradiol treatment enhances insulin-assisted glucose uptake through liganded and 
unliganded activations of ER-alpha. Estradiol is capable of stimulating an increased 
tyrosine phosphorylation of insulin receptor substrate-1 [59]. In vitro, estradiol 
activates adenosine monophosphate-activated protein kinase (AMPK) and protein 
kinase B (AKT) inducing unliganded ER signaling even in the absence of insulin 
[60]. In human adipocytes, GLUT-4 abundance shows high correlation with insulin 
responsiveness. In 3T3-L1 adipocytes, estradiol treatment facilitated glucose uptake 
via an increased expression and intracellular translocation of glucose transporters 
(GLUTs) [61].
In obesity, GLUT-4 content showed a 40% decrease in adipocyte membranes, 
while in estrogen-deficient adipocytes deriving from either lean or obese PCOS 
cases, a 36% decrease of GLUT-4 content was experienced [62]. In animal experi-
ments, female, ovariectomized high-fat-fed mice exhibited obesity, and decreased 
levels of glucose transporter 4 (GLUT4) and ER-alpha protein were found in their 
abundant visceral fatty tissue coupled with increasing insulin resistance [63].
In women, a higher ER expression in abdominal adipocytes may be associated 
with higher insulin sensitivity of fatty tissue and a lower susceptibility to inflam-
mation and fibrosis compared to men [56]. Estrogen receptor α gene expression 
levels are reduced in the adipose tissue of obese women compared to those found in 
normal weight females [64].
The identification of a mesenteric estrogen-dependent adipose gene (MEDA-4) 
revealed that estrogen signaling may selectively regulate mesenteric adipocytes in a 
depot-specific manner [65]. In ovariectomized female mice, an increased MEDA-4 
expression in mesenteric adipose tissue was capable of increasing adipose tissue 
expansion, while estradiol substitution reduced MEDA-4 expression and normal-
ized the balance of lipolysis and lipogenesis in central adipocytes.
In conclusion, estrogen-regulated genes play crucial roles in both lipogenic con-
trol and glucose uptake of adipocytes. In contrast, estrogen deficiency-associated 
insulin resistance and lipogenesis further deteriorate estrogen signaling and strongly 
decrease the expression of estrogen-regulated genes via a vicious circle [66].
6.2 Liver
In the liver, estrogen-regulated genes control the synthesis of various proteins. 
Estrogen signaling regulates lipoprotein synthesis, lipogenesis, and lipolysis in hepa-
tocytes. Estradiol controls the synthesis of blood clotting factors, including factors 
II, VII, IX, X, and plasminogen [67]. Estrogen regulates glucose uptake and glucose 
homeostasis in hepatocytes, improving insulin sensitivity [68]. In the pathologic 
conditions of the liver, estradiol treatment exerts anti-inflammatory and antineo-
plastic impacts through ER-alpha and, predominantly, ER-beta activation [69]. 
In contrast, a longer duration of estrogen deficiency increases the risk of hepatic 
fibrosis among postmenopausal women with nonalcoholic fatty liver disease [70]. 
In female mice, estrogen treatment prevents the development of insulin resistance 
and low-grade inflammation in adipose tissue [71, 72]. Recent literary data strongly 
confirm that estrogen hormone protects against the development and progression of 
hepatocellular carcinoma (HCC) [73]. Estrogen treatment also mediates antitumor 
effects in intrahepatic cholangiocarcinoma cases via a balance of ER-alpha and 
ER-beta-regulated pathways [74]. Bilateral oophorectomy in premenopausal women 
increases the risk of hepatocellular carcinoma via estrogen withdrawal [75].
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6.3 Pancreas
In pancreatic islands, the estradiol activation of ER-alpha regulates β cell 
proliferation during pancreatic development [76]. Estradiol activates the expres-
sion of insulin gene and increases insulin synthesis in the β cells [77, 78]. Estradiol 
activation of ERs inhibits apoptotic death of β cells in case of inflammatory 
insult [77]. Estradiol promotes β cell recovery after pancreatic injury [80]. In 
rodent models of type 2 diabetes, estrogen treatment reduced lipid synthesis and 
prevented β cell failure in pancreatic islets [79]. Correlations between parity and 
pancreatic cancer risk were studied in a meta-analysis of epidemiologic studies 
and the findings suggest that higher parity is associated with a decreased risk of 
pancreatic cancer [80].
6.4 Gut
Local estrogen synthesis and ER expression in the gut are important players in 
intestinal homeostasis. Estrogen signaling regulates the integrity and function of 
intestinal epithelium controls intestinal epithelial barriers and reduces intestinal 
permeability [81]. Estrogen signal provides protection against duodenal ulcer, 
inflammatory bowel disease, and colon cancer in both animal experiments and 
clinical studies [82]. Overexpression of ER-beta in healthy human colon coupled 
with its reduced expression in colon cancer suggests that the activation of ERs, 
particularly ER-beta, might be particularly involved in the estrogen-mediated 
protection against colon tumors [35].
The microbes that colonize the human gut (microbiome) may play contributory 
roles in health and disease. Intestinal microbiome participates in polysaccharide 
breakdown, nutrient absorption, inflammatory responses, and bile acid metabolism 
[83]. Gut microbiome is one of the principal regulators of circulating estrogen 
levels [84]. Microbes in the gut regulate estrogen levels through secretion of 
β-glucuronidase, an enzyme that converts conjugated estrogens into their biologi-
cally active forms. Lower microbial density or a dysbiosis of gut microbiome leads 
to a decrease in estrogen deconjugation and results in a reduction of both luminal 
and circulating free estrogen levels.
The low level of luminal estrogens induces gut diseases included inflammation 
and cancer, while an associated decrease in circulating estrogens may contribute to 
the development of systemic diseases including obesity and type 2 diabetes.
In medical practice, a fecal microbiome transplant (FMT) from healthy 
individuals to ill obese patients seems to be a promising way to improve the gut 
microbiome and for the treatment of obesity and associated metabolic syndrome 
[85]. Presumably, FMT may provide estrogen hormones and estrogen receptors for 
recipient patients, which beneficially restore intestinal estrogen signaling besides 
the re-colonization of microbes capable of increasing free estrogen levels.
In conclusion, alterations in the density and composition of gut microbiome 
deteriorate the metabolic profile of omental and mesenteric adipose tissues via 
deficient estrogen signaling and lead to the development of abdominal obesity and 
metabolic syndrome.
6.5 Kidney
Estrogens have nephroprotective effects. The most important actions of estrogen 
hormones are represented by the protective effects attenuating glomerulosclerosis 
and tubulointerstitial fibrosis. Estrogens exert favorable effects on renal osteodys-
trophy via an improvement of phosphorus-calcium transport equilibrium in renal 
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tubules [86]. Recently, a meta-analytic study supported that oral contraceptive use 
may reduce the risk of kidney cancer in women, especially for long-term users [87].
6.6 Cardiovascular system
Premenopausal women have a much lower incidence and prevalence of cardio-
vascular diseases (CVDs) compared to men of the same age [88]. This sex difference 
in favor of women suddenly disappears after menopause, suggesting that reduced 
levels of ovarian hormones constitute a major risk factor for the development of 
CVD in postmenopausal women.
In central obesity, the associated insulin resistance results in a compensatory 
high insulin and IGF-1 synthesis stimulating ovarian androgen production at the 
expense of reduced estrogen synthesis [89]. Hyperinsulinemia promotes adrenal 
androgen synthesis as well by means of an increased adrenal sensitivity to adreno-
corticotropin [90, 91]. Excessive androgen synthesis would provide precursors for 
an increased estrogen production; however, in insulin-resistant patients, gonads 
exhibit a decreased capacity to convert androgen to estrogen attributed to a reduc-
tion of aromatase enzyme activity [92].
Estrogens are cardioprotective hormones having crucial role in the maintenance 
of physiologic serum lipid levels. Postmenopausal hormone replacement therapy 
may reduce the risk of cardiovascular diseases via lowering total cholesterol, LDL 
cholesterol, and triglyceride levels [93]. Estrogens show antihypertensive activity 
as well. It is capable of downregulating the components of the renin-angiotensin 
system (RAS) [94]. Estradiol inhibits the excessive synthesis of vasoconstrictor 
endothelin and improves endothelial dysfunction [95]. In animal experiments, 
estrogen receptor-alpha mediated the protective effects of estrogen in response to 
vascular injury [96].
The risk of mortality for ischemic heart disease is highly increased in patients 
with left-sided breast cancer as they receive a higher dose of radiation therapy 
affecting the heart than patients with right-sided tumors [97]. This correlation may 
be explained by the destructive effect of radiation on the estrogen-synthesizing 
epicardial fatpad.
7.  Secretory functions of abdominal adipose tissue in healthy lean and 
obese patients
Abdominal adipose tissue has crucial physiological secretory functions [47]. 
Sex steroids, adipokines, cytokines, and growth factors are important signaling 
molecules in adipose tissue and their well-regulated activation ensures the health of 
the whole body.
In central obesity, extreme fat accumulation and a concomitant insulin resis-
tance of abdominal adipose tissue deteriorate all regulatory functions of adipocytes. 
Dysregulation of adipocyte signaling induces an alarm reaction in all adjacent 
visceral organs and they inform adipocyte ERs about their functional difficulties via 
signaling molecules. ERs in adipocytes recognize the emergency situation and may 
initiate the restoration of ER signaling through increased estrogen synthesis and 
enhanced liganded and unliganded activations of ERs [98].
7.1 Sexual steroids
In adipose tissue, suitable estrogen signaling regulates the expression of numer-
ous genes and the harmonized synthesis of signaling molecules [67]. In adipocytes, 
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androgen hormones are precursors for the local estrogen synthesis of aromatase 
enzyme.
7.2 Adipokines
Leptin regulates the energy balance in the hypothalamus exerting anorexino-
genic and lipolytic effects. Estrogen treatment increases the expression of leptin 
receptors amplifying the leptin-sensitivity of various cells [99]. In aromatase 
knock-out (ARKO) mice, visceral adiposity develops and three times higher 
levels of circulating leptin were found as compared with control animals [100]. 
Adiponectin is involved in various inflammatory reactions, modulations of 
endothelial functions, and is protective against insulin resistance. Oophorectomy 
increases adiponectin levels in adult mice, while it may be reversed by estradiol 
substitution [101]. Resistin level increases in parallel with obesity, which may be a 
compensatory reaction instead of being a causal factor. In subcutaneous adipocytes, 
an estradiol benzoate injection decreases resistin levels [102].
7.3 Pro-inflammatory cytokines and low-grade inflammation
Pro-inflammatory cytokines are regulatory proteins having great role in the 
maintenance of genomic stability. In obese patients, strong inflammatory reactions 
and abundantly expressed signaling molecules occurring in voluminous fatty tissue 
are mistakenly considered as being causal factors of genomic dysregulation, insulin 
resistance and its comorbidities [6, 103].
Low-grade inflammation in abundant adipose tissue may be characterized by 
increased levels of inflammatory cytokines and macrophage and T-cell infiltration 
[104]. Inflammatory cytokines, including tumor necrosis factor alpha (TNF-α) and 
interleukin-6 (IL-6), may have not only local effects on adipose tissue but also exert 
systemic effects on several organs [105]. In adipose tissue, inflammatory cytokines 
have an important role in the upregulation of estrogen synthesis. Increased pro-
inflammatory cytokine level generates an increased expression and activation of 
aromatase enzyme resulting in higher estrogen concentrations [106].
In ovariectomized mice on high-fat diet, estradiol treatment improved insulin 
sensitivity and glucose uptake in both adipose tissue and liver and at the same time, 
decreased the expression of inflammatory cytokines, included TNFα [71]. It was 
recently found that elevated levels of pro-inflammatory cytokines augment energy 
expenditure and counteract obesity from animal to human, justifying that pro-
inflammatory cytokines have beneficial effects against obesity and obesity-related 
metabolic disorders [107].
In conclusion, in obesity, deficient estrogen signaling leads to dysregulation of 
abdominal adipocytes and induces a low-grade inflammatory reaction, while estrogen 
treatment improves adipocyte signaling function and exerts anti-inflammatory effect.
7.4 Insulin-IGF system
The insulin-like growth factor (IGF) system is involved in regulation and 
control of physiologic growth and differentiation. Insulin and insulin-like growth 
factor receptors act as ligand-specific amplitude modulators regulating genes on a 
common pathway [108]. In obesity, there was a nonlinear relationship of insulin-
like growth factor (IGF)-I and IGF-I/IGF-binding protein-3 ratio with indices of 
adiposity and plasma insulin concentrations [109].
Crosstalks between signaling pathways of ERs and growth factor receptors 
(IGF-1R, EGFR, VGFR) are well known in both health and disease [110, 111]. 
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Among physiological circumstances, estrogen-activated ERs are capable of either 
stimulating or silencing cell growth and proliferation, while in tumor cells, an 
upregulation of ERs is not a proliferative stimulus, but rather, it is an initiator of 
self-directed death [11].
The IGF system comprises insulin, insulin receptor (IR), IGF-1, IGF-2, 
each with its receptor (IGF-1R, IGF-2R) as well as the IGF-binding proteins 
(IGFBPs). Proteins of the IGF system are ubiquitously expressed at different sites 
included adipose tissue [13]. In the early phases of insulin resistance, an increased 
IGF-1 level mediates increased insulin synthesis resulting in a compensatory 
hyperinsulinemia.
Estrogens regulate both insulin-like growth factor 1 (IGF-1) synthesis and the 
expression of its receptor (IGF-1R) in adipocytes. In turn, an increased synthesis of 
IGF-1 and its receptor upregulates the AKT and MAPK pathways of growth factor 
signaling, providing a possibility for an increased unliganded activation of ERs [112]. 
In an estrogen-deficient milieu, unliganded activation of ERs via IGF-1 receptor sig-
naling pathway exhibits a fundamental role in genome-wide expressions of estrogen-
regulated genes [48]. In conclusion, in obesity and insulin resistance, an increased 
expression and activity of IGF-1 receptors may be a compensatory action against the 
dysregulation of adipocytes providing a possibility for the restoration of ER signaling.
7.5 Interaction between adipocytes and immune cells
Adipocytes are in signaling crosstalk with immune cells in both healthy and 
obese adipose tissue. In lean adipose tissue, IL-4 secreted by eosinophil granulocytes 
and regulatory T (Treg) cells activate M2 type macrophages, which express arginase 
and anti-inflammatory cytokines such as IL-10. In contrast, in obese adipose tissue, 
the number of pro-inflammatory immune cells is increased coupled with a decrease 
in that of anti-inflammatory immune cells [104]. In abundant adipose tissue, neu-
trophil granulocytes are early responders to inflammatory injuries stimulating both 
M1 type macrophage infiltration and pro-inflammatory cytokine secretion.
In animal experiments, estrogens are capable of improving metabolic disorders 
and, at the same time, they exert anti-inflammatory effects [72]. In female mice, 
estrogen protects from adipocyte hypertrophy and prevents adipose tissue oxidative 
stress and inflammation. Furthermore, estrogen treatment protected female mice 
against developing liver steatosis and from becoming insulin resistant.
In conclusion, in obesity, the experienced low-grade inflammation and the increased 
synthesis of cytokines and growth factors are not causal factors of insulin resistance 
and cancer development, but rather, they are compensatory efforts so as to restore ER 
signaling. Estrogen administration seems to be a causal therapy for obesity-related 
pathologic changes, as the upregulation of ER signaling protects from insulin resistance 
and decreases inflammatory reactions. Estrogen treatment would provide quite new 
ways for the prevention and cure of obesity and obesity-related inflammation.
8. Estrogen is protective against cancer
The apparently paradoxical effects of estrogens on both the prevention and 
promotion of cancers have been debated for over 120 years. However, the phar-
maceutical development of endocrine disruptor antiestrogens could not provide 
appropriate advances in the field of anticancer fight [113].
The blockade of either estrogen-induced (liganded) or unliganded activation of 
ERs provoked a strong compensatory upregulation on the unaffected domain, while 
the unbalanced ER activation resulted in modest or even adverse tumor responses 
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and severe toxic symptoms [114]. In contrast, natural estrogens are capable of 
restoring DNA surveillance even in tumor cells leading to a self-directed death 
through a balanced liganded and unliganded transactivation of ERs, whereas they 
may not provoke genomic instability even in sky-high concentrations [115].
9. Conclusion
Changing concepts concerning the etiology of obesity and obesity-related 
diseases provide certain new strategies against these diseases.
Since estrogen-activated ERs are the chief regulators of the genomic machinery, 
a weakening or failure of ER signaling attributed to either genetic or environmental 
factors induces abundant compensatory actions for the restoration of appropriate 
estrogen signaling. When the restorative processes may compensate the regulatory 
failures, patients seem to be healthy. In contrast, when the compensatory reactions 
are insufficient, a deepening regulatory disorder develops and serious diseases may 
appear as clinical manifestations.
The causal factor of obesity is deficient estrogen signaling in both men and 
women; however, there is no direct correlation between obesity and cancer risk. 
All environmental and genetic cancer risk factors, included smoking, sedentary 
lifestyle, fat-rich diet, light deficiency, anovulatory infertility, and BRCA mutation 
strongly deteriorate estrogen signaling; however, they may or may not be associated 
with the development of obesity.
In certain cases, the weakness of estrogen regulation may induce abdominal fat 
deposition, and at the same time, the deepening insulin resistance of adipose tissue 
leads to further irreversible defects in expressions of estrogen-regulated genes. In 
obese patients, metabolic syndrome and type 2 diabetes are well-known risk factors 
for the two life-threatening disease groups of humans: cardiovascular lesions and 
malignancies, while the defect of estrogen signaling frequently remains unknown in 
the background.
In another group of patients, estrogen deficiency or ER resistance develops with-
out obesity. Defective estrogen signaling exhibits a strong direct correlation with 
insulin resistance as estrogen regulates all steps of cellular glucose uptake in the 
whole body. Moreover, the deeper the defect of estrogen surveillance, the stronger is 
the risk for serious chronic diseases included type 2 diabetes, cardiovascular lesions, 
and cancers. The strong correlation is well known between anovulatory infertility 
and an increased cancer risk for female organs, while these associations are quite 
independent of obesity.
In patients showing central obesity, the increased cytokine secretion and the 
associated low-grade inflammation in their adipose tissue are not causal factors of 
the development of insulin resistance, but rather, they are compensatory actions 
for the activation of aromatase synthesis. Similarly, in abundant adipose tissue, the 
increased synthesis of growth factors included IGF-1 and the abundant expression 
of growth factor receptors are not efforts for initiating an unrestrained cell prolif-
eration, but rather they provide unliganded pathways for increased ER activation so 
as to strengthen estrogen signaling.
In nonobese patients, deficient estrogen signaling is associated with high risk for 
premature arteriosclerotic complications and cancer development. In these cases, 
inflammatory reactions at several sites represent compensatory actions against 
estrogen deficiency via an activation of aromatase enzyme. Moreover, in patients 
with clinically diagnosed infertility, PCOS, or BRCA mutation, the increased serum 
estrogen levels are compensatory efforts against ER resistance instead of a harmful 
induction of pathologic cell proliferation. Patients with ER resistance may exhibit 
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an increased cancer risk in spite of hyperestrogenism, when the compensatory 
increased estrogen level is not sufficient for the breakthrough of ER blockade.
In conclusion, in obese patients, the causal therapy is the improvement of 
estrogen signaling in both men and women via estrogen substitution, changes in 
lifestyle, or use of natural products upregulating the genomic machinery. These 
therapies are equally protective against weight gain, metabolic disorders, inflam-
matory reactions, and obesity-related diseases including cancer. In obesity, medi-
caments working against the reparative, compensatory processes in the adipose 
tissue may induce strong counteractions via feedback mechanisms; however, the 
therapeutic results are transitory, ambiguous, and even dangerous.
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